BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025

BridgeBio Pharma to present cardiovascular data on acoramidis for ATTR-CM at ACC Annual Scientific Sessions in March 2025.

Quiver AI Summary

BridgeBio Pharma, Inc. announced that it will present cardiovascular outcomes data from its Phase 3 study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at the American College of Cardiology Annual Scientific Sessions from March 29-31, 2025. The company has been selected for five poster presentations and two moderated posters related to ATTR-CM. Key presentations include findings on acoramidis' effectiveness in improving serum TTR levels and patient classifications, as well as its impact on reducing cardiovascular-related hospitalizations and mortality. Acoramidis is noted as the first nearly complete stabilizer of TTR approved in the U.S. for treating ATTR-CM, which was generally well-tolerated by patients. BridgeBio, focused on developing solutions for genetic diseases, aims to deliver transformative medicines quickly to patients.

Potential Positives

BridgeBio Pharma will present cardiovascular outcomes data from its Phase 3 study of acoramidis at a prestigious scientific conference, showcasing its commitment to advancing research in genetic diseases.
The company has been selected to share multiple poster presentations, indicating recognition and interest from the medical community regarding its research on ATTR-CM.
Acoramidis is noted as the first near-complete stabilizer of Transthyretin approved in the U.S. for treating ATTR-CM, which highlights its innovative position in the biopharmaceutical landscape.
The press release mentions that acoramidis was generally well-tolerated, pointing to its favorable safety profile for patients.

Potential Negatives

The press release focuses on data presentations at a conference, which may suggest a lack of strong initial results from the clinical trials given that key outcomes are still being disseminated in this format rather than through more definitive publications or approvals.
The mention of side effects, even if mild, could raise concerns about drug tolerability among potential patients and healthcare providers, possibly impacting the adoption of Attruby™.

FAQ

What is the focus of BridgeBio Pharma?

BridgeBio Pharma focuses on developing biopharmaceuticals for genetic diseases, including transthyretin amyloid cardiomyopathy (ATTR-CM).

When will the data from the ATTRibute-CM study be presented?

The data will be presented at the American College of Cardiology Annual Scientific Sessions from March 29-31, 2025.

What is Acoramidis used for?

Acoramidis is used to treat patients with wild-type or variant ATTR-CM to reduce cardiovascular-related mortality and hospitalization.

What were the common side effects of Acoramidis?

The most common side effects of Acoramidis included mild diarrhea and abdominal pain, which typically resolved without discontinuation of the drug.

How can patients access BridgeBio medications?

BridgeBio offers a suite of programs designed to help patients access their medicines effectively.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $197,760,000
GLOBAL INVESTORS LP VIKING sold 3,065,616 shares for an estimated $106,989,998
NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 9 sales selling 733,932 shares for an estimated $26,060,471.
BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 5 sales selling 84,804 shares for an estimated $2,992,985.
HANNAH VALANTINE sold 12,875 shares for an estimated $419,499

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BBIO Hedge Fund Activity

We have seen 143 institutional investors add shares of $BBIO stock to their portfolio, and 138 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FARALLON CAPITAL MANAGEMENT LLC added 2,448,000 shares (+140.1%) to their portfolio in Q4 2024, for an estimated $67,173,120
CITADEL ADVISORS LLC removed 1,686,753 shares (-57.3%) from their portfolio in Q4 2024, for an estimated $46,284,502
WOODLINE PARTNERS LP added 1,261,772 shares (+132.9%) to their portfolio in Q4 2024, for an estimated $34,623,023
PERCEPTIVE ADVISORS LLC removed 1,215,346 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $30,942,709
PARADIGM BIOCAPITAL ADVISORS LP removed 1,089,492 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $27,738,466
PICTET ASSET MANAGEMENT HOLDING SA removed 995,585 shares (-35.5%) from their portfolio in Q4 2024, for an estimated $27,318,852
ALYESKA INVESTMENT GROUP, L.P. added 940,415 shares (+inf%) to their portfolio in Q4 2024, for an estimated $25,804,987

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 10/24/2024

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 2 analysts offer price targets for $BBIO in the last 6 months, with a median target of $45.5.

Here are some recent targets:

David Lebowitz from Citigroup set a target price of $45.0 on 10/24/2024
Mani Foroohar from Leerink Partners set a target price of $46.0 on 10/17/2024

Full Release

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.

Flatboard Poster Presentations:
Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy
Presenter: Margot Davis, M.D. of Vancouver General Hospital, CA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Acoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET

In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR Levels
Presenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Robustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity Analyses
Presenter: Jan Griffin, M.D. of Medical University of South Carolina, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET

Acoramidis-mediated Early Increase in Serum Transthyretin Level Reduces Cardiovascular-related Hospitalizations and Mortality: Insights from the ATTRibute-CM Study
Presenter: Nitasha Sirwat, M.D. of UChicago Medicine, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET

Moderated Posters:
Primary Endpoint Efficacy Results in the ATTRibute-CM Study: Pre-specified Sensitivity Analyses Addressed Tafamidis Use
Presenter: Daniel P. Judge, M.D. of Medical University of South Carolina, USA
Date: Saturday, March 29 at 10:06 am CT/11:06 am ET

Geographic Healthcare Disparities and Diagnostic Trends Among Patients with Transthyretin Amyloid Cardiomyopathy
Presenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USA
Date: Saturday, March 29 at 10:54 am CT/11:54 am CT

About Attruby™ (acoramidis)
Attruby is the first near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive suite of programs to help patients access our medicines.

About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn , Twitter and Facebook .

BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact @bridgebio.com
(650)-789-8220